Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) compound that effectively suppresses PCSK-9 transcription. It proves promising in the investigation of hyperlipidemia and cardiovascular disease (CVD).

Inclisiran (ALN-PCSsc), a double-stranded small interfering RNA (siRNA) compound, serves as the antisense of itself and targets PCSK-9 transcription inhibition. It is employed in the study of hyperlipidemia and cardiovascular disease (CVD) [1].

Inclisiran (unconjugated/naked) is a double-stranded small interfering RNA (siRNA) that lacks GalNAc conjugation. This compound selectively inhibits the transcription of PCSK-9, making it applicable in the research of hyperlipidemia and cardiovascular disease (CVD) [1].

Inclisiran AS(3n-2), an antisense variant of Inclisiran, features a 2 bp spacer followed by 3 random N sites. Inclisiran itself is a double-stranded small interfering RNA (siRNA) molecule designed to suppress PCSK-9 transcription, thereby reducing LDL cholesterol levels [1].